IP Library Granted Patent US 11,046,762
Granted Patent B2
US 11,046,762 · App. 16/601,065 · Granted Jun 29, 2021

Cross-linkers and their uses

Inventors: Ravi V. J. Chari (Newton, MA); Robert Yongxin Zhao (Lexington, MA); Yelena Kovtun (Stow, MA); Rajeeva Singh (Framingham, MA); Wayne C. Widdison (Belmont, MA)
Assignee: IMMUNOGEN, INC.
C07K16/28A61K31/5365A61K47/65A61K47/6809A61K47/6849C07D207/46C07K5/0202C07K5/06026C07K5/0806C07K5/0819Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,046,762
App. No.
16/601,065
Granted
Jun 29, 2021
Kind
B2
Abstract

Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.

Claims (14)

1. A compound of formula (IV):

wherein:

Y′ represents a functional group that enables reaction with a cell-binding agent, wherein Y′ is N-hydroxysuccinimide ester;

D represents a cytotoxic drug linked to the cell-binding agent by a disulfide, thioether, thioester, peptide, hydrazone, ester, ether, carbamate, or amide bond;

one of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is a charged substituent selected from SO 3 − or X-SO 3 , and the rest are H;

l and m are each 0;

n is 1; and

Z is absent.

2. The compound of claim 1 , wherein the cytotoxic drug is a maytansinoid.

3. The compound of claim 2 , wherein the cytotoxic drug is DM1 or DM4.

4. The compound of claim 2 , wherein the cytotoxic drug is DM4.

5. The compound of claim 1 , wherein D represents a maytansinoid drug linked to the cell-binding agent by a disulfide bond.

6. The compound of claim 5 , wherein the maytansinoid drug is DM1 or DM4.

7. The compound of claim 5 , wherein the maytansinoid drug is DM4.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Feb 12, 2024
From: BIOPHARMA CREDIT PLC
To: IMMUNOGEN, INC.; IMMUNOGEN SWITZERLAND GMBH
Reel/Frame 066553/0109 →
PATENT SECURITY AGREEMENT Recorded Apr 6, 2023
From: IMMUNOGEN, INC.; IMMUNOGEN SWITZERLAND GMBH
To: BIOPHARMA CREDIT PLC
Reel/Frame 063282/0894 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2020
From: CHARI, RAVI V.J.; ZHAO, ROBERT YONGXIN; KOVTUN, YELENA; SINGH, RAJEEVA; WIDDISON, WAYNE CHARLES
To: IMMUNOGEN, INC.
Reel/Frame 051809/0459 →
Continuity (9)
Continuation 15911571 · Mar 5, 2018
Continuation 15293579 · Oct 14, 2016
Continuation 14713419 · May 15, 2015
Continuation 14080377 · Nov 14, 2013
Continuation 13542126 · Jul 5, 2012
Division 12433604 · Apr 30, 2009
Provisional Application 61147966 · Jan 28, 2009
Provisional Application 61049291 · Apr 30, 2008
Related Publication 20200148764A1 · May 14, 2020